Send to

Choose Destination
BMC Health Serv Res. 2018 Jun 5;18(1):413. doi: 10.1186/s12913-018-3226-3.

Evaluation of a cancer patient navigation program ("Onkolotse") in terms of hospitalization rates, resource use and healthcare costs: rationale and design of a randomized, controlled study.

Author information

"Onkolotse" Cancer Patient Navigation Project, Sächsische Krebsgesellschaft e.V, Schlobigplatz 23, 08056, Zwickau, Germany.
MSD SHARP & DOHME GMBH, Lindenplatz 1, 85540, Haar, Germany.
"Onkolotse" Cancer Patient Navigation Project, Sächsische Krebsgesellschaft e.V, Schlobigplatz 23, 08056, Zwickau, Germany.
StatConsult Gesellschaft für klinische und Versorgungsforschung mbH, Halberstädter Strasse 40a, 39112, Magdeburg, Germany.



Concepts for the nursing and care of cancer patients through a "navigation service" have attracted much interest. However, there is still room for improvement in terms of their funding and coverage. The Saxon Cancer Society designed a prospective, randomized, multicenter, longitudinal study with a view to determining the positive effects of a cancer patient navigator program. The objective of this ongoing study is to evaluate the impact of the cancer patient navigation program on cancer patients and cost bearers in Germany.


The study population in this evaluation comprises cancer patients with gastric carcinoma, pancreatic carcinoma, colorectal cancer, melanoma or gynecological cancer who have been hospitalized at least once at one of the study centers as well as their relatives, outpatient and inpatient physicians, and cancer nurses. It is planned to randomize 340 cancer patients (stomach, colonic/rectal cancer, gynecological cancer, melanoma) at five centers to an intervention group (care by patient navigators based on standardized operating procedures) or a control group in a one-to-one ratio. The primary target parameter is the number of hospitalizations within the 12-month intervention period. The participants are asked to complete various questionnaires on patient-related outcomes at baseline and at 3 and 12 months (SF 36, HADS, PAM 13, and others). Data on drug therapy, utilization of health services, and medical expenses will also be analyzed.


For the first time, the study will provide data on the effectiveness of a patient support program in cancer care in Germany from a randomized trial with a high level of evidence.


The study has been registered under DRKS00013199 in the German Clinical Trials Register.


Disease costs; Disease management; Healthcare competence; Healthcare research; Oncology; Patient-relevant results; Psychosocial care; Treatment outcomes

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center